WOSCOPS


Also found in: Acronyms.

WOSCOPS

 Cardiology A trial–West of Scotland Coronary Prevention Study–of the effect of pravastatin on M&M–risk of CHD, malignancy and other outcome data–in men with hypercholesterolemia. See Lipid-lowering therapy, Pravastatin. Cf MAAS, PLAC I, PLAC II, 4S–Scandanavian Simvastatin Survival Study.
References in periodicals archive ?
At that point, WOSCOPS leaders advised study participants' primary care physicians to seriously consider putting their patients on long-term statin therapy.
For WOSCOPS participants who got a 20% drop in LDL during 5 years of pravastatin from a baseline of 190 mg/dL, as was typical, the number of patients who needed to be treated (NNT) for 5 years to prevent one cardiovascular hospital admission over a 20-year period was six.
White said, but the key to why the legacy effect was seen in WOSCOPS despite the use of pravastatin--a less-potent statin--but not to date in other statin trials may lie in the fact that WOSCOPS was a primary prevention study and its participants had the youngest mean age of all the major statin trials.
Disclosures: WOSCOPS was sponsored by Bristol-Myers Squibb.
12 AFCAPS/TexCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study; ALLHAT-LLT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart AttackTrial; ASCOT-LLA, Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm; CHD, coronary heart disease; hsCRP, high-sensitivity C-reactive protein; JUPITER, Justification for me Use of Statins in Prevention: an Intervention Trial Evaluating HosuvasTatin; LDL-C, low-density lipoprotein cholesterol; MEGA, Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese; MI, myocardial infarction; WOSCOPS, West of Scotland Coronary Prevention Study.
Currently, WOSCOPS and AFCAPS/TexCAPS are the only major primary prevention trials of lipid-lowering therapy in elderly populations.
Further, the association between KIF6 and statin benefit was established in genetic studies of four randomized, controlled clinical trials (CARE, WOSCOPS, PROVE IT, and PROSPER) in which statin therapy was found to reduce CHD events in carriers of the KIF6 variant.
The association between increased risk of coronary events and the Arg variant of the KIF6 Trp719Arg polymorphism in both CARE and WOSCOPS was independent of traditional CHD risk factors, which was also true for the other studies mentioned in this press release.
The genetic association studies were performed among 2,715 patients of the CARE trial and among 1,561 patients of a nested case-control study of the WOSCOPS trial.
The WOSCOPS study was led by Professor James Shepherd.
The WOSCOPS study was led by Professor James Shepherd, Department of Biochemistry, University of Glasgow and Royal Infirmary.
The genetic association studies were performed with samples from the male subjects of the CARE trial (2,523 men) and with samples from the all-male WOSCOPS trial (1,562 participants in a nested case control study).